Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
13 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsIn CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (44.9KB)
(World News Science)

 
 

17 april 2018 05:31:12

 
In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (44.9KB)
(World News Science)
 




April 17, 2018 In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (PRINCETON, NJ, April 16, 2018) - Bristol-Myers Squibb Company (NYSE: BMY) announced two-year overall survival (OS) data from CheckMate -141, a Phase 3 open-label, randomized trial evaluating Opdivo (nivolumab) compared with investigator`s choice chemotherapy (cetuximab, docetaxel or methotrexate)...
 
9 viewsCategory: Science
 
Emily Binder Receives Missouri Corn Scholarship
(World News Science)
Cole Diggins Receives Missouri Corn Scholarship
(World News Science)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2018 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn